Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.01055 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.01055 32655548!7325873!32655548     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 1055 Nephropedia Template TP {{tp|p=32655548|t=2020. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity |pdf=|usr=}}{{32655548}} gab.com Text Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32655548 #FOAvip Dengue is one of the most frequently transmitted mosquito-borne diseases in the world, which creates a significant public health concern globally, especially in tropical and subtropical countries. It is estimated that more than 390 million people are infected with dengue virus each year and around 96 million develop clinical pathologies. Dengue infections are not only a health problem but also a substantial economic burden. To date, there are no effective antiviral therapies and there is only one licensed dengue vaccine that only demonstrated protection in the seropositive (Immune), naturally infected with dengue, but not dengue seronegative (Naive) vaccines. In this review, we address several immune components and their interplay with the dengue virus. Additionally, we summarize the literature pertaining to current dengue vaccine development and advances. Moreover, we review some of the factors affecting vaccine responses, such as the pre-vaccination environment, and provide an overview of the significant challenges that face the development of an efficient/protective dengue vaccine including the presence of multiple serotypes, antibody-dependent enhancement (ADE), as well as cross-reactivity with other flaviviruses. Finally, we discuss targeting T follicular helper cells (Tfh), a significant cell population that is essential for the production of high-affinity antibodies, which might be one of the elements needed to be specifically targeted to enhance vaccine precision to dengue regardless of dengue serostatus. Twit Text FOAVip Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32655548 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32655548 #FOAvip English Wikipedia <ref>{{Cite pmid|32655548}}</ref> Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity #MMPMID32655548 Izmirly AM; Alturki SO; Alturki SO; Connors J; Haddad EK Front Immunol 2020[]; 11 (ä): 1055 PMID32655548show ga Dengue is one of the most frequently transmitted mosquito-borne diseases in the world, which creates a significant public health concern globally, especially in tropical and subtropical countries. It is estimated that more than 390 million people are infected with dengue virus each year and around 96 million develop clinical pathologies. Dengue infections are not only a health problem but also a substantial economic burden. To date, there are no effective antiviral therapies and there is only one licensed dengue vaccine that only demonstrated protection in the seropositive (Immune), naturally infected with dengue, but not dengue seronegative (Naive) vaccines. In this review, we address several immune components and their interplay with the dengue virus. Additionally, we summarize the literature pertaining to current dengue vaccine development and advances. Moreover, we review some of the factors affecting vaccine responses, such as the pre-vaccination environment, and provide an overview of the significant challenges that face the development of an efficient/protective dengue vaccine including the presence of multiple serotypes, antibody-dependent enhancement (ADE), as well as cross-reactivity with other flaviviruses. Finally, we discuss targeting T follicular helper cells (Tfh), a significant cell population that is essential for the production of high-affinity antibodies, which might be one of the elements needed to be specifically targeted to enhance vaccine precision to dengue regardless of dengue serostatus. |Adaptive Immunity[MESH] |Antibody-Dependent Enhancement[MESH] |Cross Reactions[MESH] |Dengue Vaccines/adverse effects/*immunology[MESH] |Dengue Virus/immunology[MESH] |Dengue/epidemiology/*immunology/*prevention & control[MESH] |Drug Development/methods/trends[MESH] |Flavivirus/immunology[MESH] |Host Microbial Interactions/immunology[MESH] |Humans[MESH] |Immunity, Innate[MESH] |Models, Immunological[MESH]Challenges in Dengue Vaccines Development: Pre-existing Infections and(epmc).pdf DeepDyve Pubget Overpricing